Atyr Pharma Inc (ATYR) Stock Price, Quote & News

Company Profile

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 731 8389

Fax: 858 731 8394

Website: atyrpharma.com

Address:

10240 Sorrento Valley Road, Suite 300, San Diego, United States

Indialli1309 Jul. 31 at 9:21 PM

$ATYR https://investors.atyrpharma.com/sec-filings/sec-filing/8-k/0001339970-26-000042 This is interesting!

3 · Reply

Wallace911 Jul. 31 at 8:56 PM

$ATYR SEC Filing Details Document Details Form 8-K Filing Date Jul 31, 2026 Document Date Jul 30, 2026 Form Description Report of unscheduled material events or corporate event Filing Group Current Reports Company aTyr Pharma Issuer aTYR PHARMA INC

1 · Reply

prm2021 Jul. 31 at 1:27 PM

$ATYR this is going to be next REPL once approved. Will get close to $8-10 as per extensive AI analysis

1 · Reply

SpartanTrader117 Jul. 30 at 2:36 AM

$ATYR they decreased their position majorly. They used to have over 6 million shares.

0 · Reply

SpartanTrader117 Jul. 30 at 2:33 AM

$ATYR they are afraid on earnings report August 6th maybe?

0 · Reply

Stwanker Jul. 28 at 5:52 AM

$ATYR latest 13G black rock just revealed 1.8% ownership in this company. That’s 1.75 million shares. Another institutional confidence 🚀🚀 NFA

1 · Reply

bigron8671 Jul. 27 at 2:07 PM

$ATYR 6m more bought back and 13m over the last 2 months

1 · Reply

SpartanTrader117 Jul. 26 at 9:21 PM

$ATYR earnings coming up August 6

0 · Reply

SpartanTrader117 Jul. 24 at 11:16 PM

$ATYR negative

0 · Reply

Unknown_Stuntman Jul. 24 at 1:13 PM

$ATYR any catalysts coming to float this sewer pickle?

0 · Reply

Ethos Reports Second Quarter Fiscal Year 2026 Financial Results

LIFE

Jul 21, 2026, 9:07 AM EDT - 14 days ago

Ethos and North American Expand Their Indexed Universal Life Product Offering to include Children

LIFE

Jul 15, 2026, 8:00 AM EDT - 20 days ago

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

Jul 2, 2026, 4:35 PM EDT - 4 weeks ago

Ethos to Announce Second Quarter 2026 Financial Results on August 3, 2026

LIFE

Jun 25, 2026, 3:30 PM EDT - 5 weeks ago

aTyr Pharma Transcript: Life Sciences Virtual Investor Forum

Jun 4, 2026, 3:45 PM EDT - 2 months ago

aTyr Pharma Transcript: Jefferies Global Healthcare Conference 2026

May 26, 2026, 3:08 PM EDT - 2 months ago

Forget the SpaceX IPO. These 2 New Stocks Stand Out Right Now.

LIFE PTRN

May 21, 2026, 9:07 AM EDT - 2 months ago

Ethos Partners with Baseball Legend David Ortiz to Champion Life Insurance as a Family Financial Essential

LIFE

2026-05-20T13:00:12.000Z - 2 months ago

aTyr Pharma upgraded to Buy from Hold at Freedom Broker

May 15, 2026, 4:30 PM EDT - 2 months ago

Ethos to Present at Upcoming Investor Conferences

LIFE

2026-05-15T15:42:31.000Z - 2 months ago

aTyr Pharma reports Q1 EPS (11c), consensus (15c)

May 15, 2026, 8:00 AM EDT - 2 months ago

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

May 15, 2026, 7:00 AM EDT - 2 months ago

aTyr Pharma Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

aTyr Pharma Earnings release: Q1 2026

May 13, 2026, 4:35 PM EDT - 2 months ago

Ethos Announces Early Lock-Up Release

LIFE

May 13, 2026, 4:01 PM EDT - 2 months ago

aTyr Pharma to Participate in Upcoming Investor Conferences

2026-05-11T23:05:03.000Z - 3 months ago

aTyr Pharma provides regulatory update on efzofitimod following Type C meeting

May 11, 2026, 4:30 PM EDT - 3 months ago

aTyr Pharma Transcript: Study update

May 11, 2026, 4:30 PM EDT - 3 months ago

aTyr Pharma Press release: Study update

May 11, 2026, 4:30 PM EDT - 3 months ago

aTyr Pharma Slides: Study update

May 11, 2026, 4:01 PM EDT - 3 months ago

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

May 6, 2026, 4:05 PM EDT - 3 months ago

Ethos Reports First Quarter Fiscal Year 2026 Financial Results

LIFE

May 5, 2026, 9:07 AM EDT - 3 months ago

Ethos Launches ChatGPT App To Bring Instant Life Insurance Estimates to 900 Million Users

LIFE

Apr 23, 2026, 9:07 AM EDT - 3 months ago

Ethos Collaborates with Liberty Mutual to Deliver a Modern, Digital-First Life Insurance Experience

LIFE

Apr 2, 2026, 4:05 PM EDT - 4 months ago

Ethos to Announce First Quarter 2026 Financial Results on May 6, 2026

LIFE

Mar 26, 2026, 8:00 AM EDT - 4 months ago

aTyr Pharma Proxy statement: Proxy filing

Mar 26, 2026, 8:00 AM EDT - 4 months ago

aTyr Pharma Proxy statement: Proxy filing

Mar 24, 2026, 4:05 PM EDT - 4 months ago

Ethos and Banner Life Expand Offering to Bring Final Expense Coverage to More Families

LIFE

Mar 12, 2026, 8:00 AM EDT - 5 months ago

aTyr Pharma Proxy statement: Proxy Filing

Mar 11, 2026, 8:00 AM EDT - 5 months ago

aTyr Pharma Transcript: Leerink Global Healthcare Conference 2026

2026-03-05T21:05:56.000Z - 5 months ago

aTyr Pharma reports Q4 EPS (14c), consensus (17c)

Mar 5, 2026, 4:01 PM EST - 5 months ago

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

Mar 5, 2026, 3:00 PM EST - 5 months ago

aTyr Pharma Annual report: Q4 2025

Mar 5, 2026, 3:00 PM EST - 5 months ago

aTyr Pharma Earnings release: Q4 2025

Feb 26, 2026, 4:06 PM EST - 5 months ago

Ethos to Participate in The Citizens Technology Conference

LIFE

Feb 25, 2026, 4:05 PM EST - 5 months ago

Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial Results

LIFE

Feb 20, 2026, 4:01 PM EST - 5 months ago

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 18, 2026, 8:00 AM EST - 5 months ago

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

Feb 5, 2026, 4:05 PM EST - 6 months ago

Ethos to Announce Fourth Quarter 2025 Financial Results on February 25, 2026

LIFE

Feb 3, 2026, 2:46 PM EST - 6 months ago

The IPO Market Faces a Busy Week. These Stocks Are Making Their Debuts.

FPS LFTO YSS

2026-02-03T13:10:35.000Z - 6 months ago

aTyr Pharma announces U.S. FDA accepted meeting request for efzofitimod

Feb 3, 2026, 8:00 AM EST - 6 months ago

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

Jan 29, 2026, 12:30 PM EST - 6 months ago

Insurance platform Ethos Technologies valued at $1.2 billion in Nasdaq debut

Jan 28, 2026, 10:38 PM EST - 6 months ago

Ethos Announces Pricing of Initial Public Offering

Jan 28, 2026, 9:05 PM EST - 6 months ago

Ethos Technologies prices US IPO at $19/share, Bloomberg News reports

Jan 7, 2026, 8:01 AM EST - 7 months ago

Ethos and North American Collaborate to Offer Accumulation Indexed Universal Life Product

Dec 18, 2025, 8:01 AM EST - 8 months ago

Ethos and Aflac Partner to Bring Supplemental Health Product Suite to Independent Distribution

Dec 15, 2025, 2:45 PM EST - 8 months ago

Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders

Dec 8, 2025, 3:25 AM EST - 8 months ago

aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR

Dec 2, 2025, 1:00 PM EST - 8 months ago

aTyr Pharma Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-11-25T15:09:57.000Z - 9 months ago

aTyr Pharma Faces Class Action after Clinical Trial Failure Raises Investor Concerns

2025-11-06T21:26:32.000Z - 9 months ago

aTyr Pharma reports Q3 EPS (26c), consensus (18c)

Nov 6, 2025, 4:00 PM EST - 9 months ago

aTyr Pharma Earnings release: Q3 2025

Nov 6, 2025, 4:00 PM EST - 9 months ago

aTyr Pharma Quarterly report: Q3 2025

2025-09-30T10:20:48.000Z - 11 months ago

aTyr Pharma reports clinical benefit for efzofitimod across multiple diseases

2025-09-29T20:40:08.000Z - 11 months ago

Piper Sandler healthcare analysts hold an analyst/industry conference call

2025-09-15T20:30:25.000Z - 11 months ago

aTyr Pharma downgraded to Sector Perform from Outperform at RBC Capital

2025-09-15T18:00:09.000Z - 11 months ago

Wells Fargo downgrades aTyr Pharma on efzofitimod Phase 3 failure

Indialli1309 Jul. 31 at 9:21 PM

$ATYR https://investors.atyrpharma.com/sec-filings/sec-filing/8-k/0001339970-26-000042 This is interesting!

3 · Reply

Wallace911 Jul. 31 at 8:56 PM

1 · Reply

prm2021 Jul. 31 at 1:27 PM

$ATYR this is going to be next REPL once approved. Will get close to $8-10 as per extensive AI analysis

1 · Reply

SpartanTrader117 Jul. 30 at 2:36 AM

$ATYR they decreased their position majorly. They used to have over 6 million shares.

0 · Reply

SpartanTrader117 Jul. 30 at 2:33 AM

$ATYR they are afraid on earnings report August 6th maybe?

0 · Reply

Stwanker Jul. 28 at 5:52 AM

$ATYR latest 13G black rock just revealed 1.8% ownership in this company. That’s 1.75 million shares. Another institutional confidence 🚀🚀 NFA

1 · Reply

bigron8671 Jul. 27 at 2:07 PM

$ATYR 6m more bought back and 13m over the last 2 months

1 · Reply

SpartanTrader117 Jul. 26 at 9:21 PM

$ATYR earnings coming up August 6

0 · Reply

SpartanTrader117 Jul. 24 at 11:16 PM

$ATYR negative

0 · Reply

Unknown_Stuntman Jul. 24 at 1:13 PM

$ATYR any catalysts coming to float this sewer pickle?

0 · Reply

stefano62 Jul. 24 at 12:41 PM

$ATYR unfortunately the Spike After the announcements of the actual submission of the IND has spired

1 · Reply

AtariLynx Jul. 23 at 5:19 AM

$ATYR they have time until November

0 · Reply

AtariLynx Jul. 22 at 7:17 PM

$ATYR r/s incoming?

0 · Reply

AtariLynx Jul. 21 at 11:16 AM

$ATYR sell at .60 could be enough 🤣👍🏻

0 · Reply

SpartanTrader117 Jul. 21 at 12:23 AM

$ATYR buy again at .43 sell at .65. Rinse and repeat.

0 · Reply

cea Jul. 19 at 9:44 PM

$ATYR $SLS Pardon me, but absolute non-sense. Zero similarities. No reason to give them any credit…any fool can be right once.

0 · Reply

paulstoxk Jul. 19 at 9:42 PM

$SLS $ATYR sls =/= atyr Their trial failed to show statistically significant steroid reduction versus placebo. Our trial is against a toxic BAT that has never performed as well and for as long as GPS. Might as well compare sls to a dotcom bubble stock. Blocked.

3 · Reply

WenABVEAudit Jul. 19 at 9:27 PM

$SLS not trying to prop up the guy Steve rogers or whatever his name is but tbh the only thing that’s giving me a bit of apprehension and that he could be right here is that both he and that other scum bag pharma bro were right on $ATYR , which I lost a lot of $ on…

4 · Reply

AtariLynx Jul. 17 at 4:49 PM

$ATYR it’s warming up the engines.

2 · Reply

Ucke77 Jul. 17 at 1:42 PM

$ATYR Hey Wallace911, Indialli1309, the rocket ran out of fuel and probably crashed into the basement. Great prediction! But next week it'll definitely be right.

2 · Reply

Merlintrader Jul. 16 at 3:45 PM

$GANX Biotech Radar July 16, 2026: Gain Therapeutics, aTyr Pharma and Medicus Pharma — $GANX $ATYR $MDCX https://www.merlintrader.com/biotech-radar-july16-2026/

1 · Reply

ajmrtxl Jul. 16 at 1:10 PM

$ATYR 's latest data on SqueezeFinder

2 · Reply

Market Cap	47.62M
Revenue (ttm)	190,000.00
Net Income (ttm)	-74.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-39,010.53%
Debt to Equity Ratio	0.00

Volume	613,204
Avg Vol	2,143,754
Day's Range	N/A - N/A
Shares Out	98.05M
Stochastic %K	67%
Beta	0.52
Analysts	Sell
Price Target	$2.75